hemp Archives - Green Market Report

StaffStaffJuly 29, 2019
shutterstock_1093553171.jpg

14min13740

Guest submission from Ivan Green.

Hundreds of people have been benefited from using Cannabidiol (CBD) – a substance scientifically proven to be safe for human consumption – even for children! 

It not only has a wide range of therapeutic benefits but also has been useful for treating numerous serious ailments and disorders. 

However, not all products touted as “natural CBD oil” are actually as natural they claim to be. 

Natural CBD is admittedly safe. But they don’t include products that are made from synthetic lab-produced cannabinoids or contain contaminants, high levels of hallucinatory cannabinoids like Tetrahydrocannabinol (THC) or other harmful substances. 

Using such products will do more damage to you than simply making you fail a drug test. You can end up falling horribly sick or even dead! 

With the growing popularity of CBD products, some unscrupulous cannabis growers and CBD oil manufacturers are taking advantage of loopholes in the existing regulations and the vulnerabilities of the common man in this country to push their business forward with cheap, artificial and untested products in the name of CBD oil. 

Cheap Synthetic CBD 

From a once non-existent market category to a $1 billion industry, the hemp-derived CBD has become a booming industry today. 

But, it was disheartening to hear of 50 people falling severely ill after using CBD oil in Utah last year. It is worse when we find out that the oil that those people unwittingly smoked up thinking it was genuine CBD vape oil did not even contain any natural cannabinoid, but contained some lab-produced synthetic cannabinoids

The reason why people fall for these products are usually because of three reasons: 

  1. Their low price, 
  2. Tall promises of curing all health conditions, and 
  3. Claims of not being detected on a drug test. 

The unfortunate thing is these people were plain and simple duped! The company lied to its customers, and as a result, harmed them in ways that their unwary consumers were not prepared for. 

These dangerous designer drugs had prompted the US Centers for Disease Control and Prevention (CDC) to issue a nationwide health warning about these man-made synthetic cannabinoids. 

This is precisely why most reputed brands who sell genuine products are obligated to present their proof of their genuineness to their customers. They post the results of their products tested by third-party laboratories, also known as a Certificate of Analysis, which tests not only for synthetic components, but also other contaminants like heavy metals and pesticides and heavy metals as well as natural cannabinoids that possess hallucinatory effects, like THC (tetrahydrocannabinol, a natural cannabinoid found in cannabis plants).

Spice 

Known by different names – K2, Spice, Mr. Happy, Scooby Snax, and Kronic – is nothing but a group of lab-made synthetic cannabinoids that have been associated with a lot of people falling sick.

Originally designed by scientists for research, this drug is made from dried plant materials, sprayed with hallucinogenic chemicals. 

However, with the production method of this drug being published in scientific journals as part of their research, this knowledge also fell into the hands of some unscrupulous, over-ambitious drug makers, who used it to produce illicit drugs.

Once it hit the market, it came out as a new form of marijuana and people started rolling up the plant material into “joints” and smoking them like marijuana. 

This synthetic marijuana or fake weed is also sold in a liquid form that can be inhaled through a vape pen or mixed in tea to consume. 

Although these are man-made cannabinoids, it has the same effect on the human brain (especially the endocannabinoid system) as THC, but with far more intensity (even up to 100 times more intense). 

With no way to regulate them, there is no saying which hallucinogens are being used by the manufacturers to make their products.

The “Free” Scam 

Nothing in the CBD world is free. It simply can’t be. Manufacturing a bottle of genuine, natural CBD oil is expensive. If anybody tells you otherwise, be sure you are being tricked. 

While searching for CBD oil online, if you come across phrases like: 

  • Best Price, Limited Offer
  • Limited-Time Special Offer 
  • Special Discount For Only Today

Then be alert. Look up the brand and find out if their products are genuine. 

And if you see:

  • CBD oil free trial 
  • Or, they tell you to submit your credit card to free stuff 

DON’T BUY, REPORT. 

Some “free sample” offers are nothing more than hidden subscription ploy to force you to give away your credit/debit card details, which they will use to forcefully sell you low-quality products. You may even find it difficult to cancel the alleged subscription. You may have to call up your bank or credit card company to cancel their card to stop payments. 

Some other scammers will charge you more for what they are selling by simply calling it shipping and processing fee (while they send you a low-quality product). 

Quite a few reputed CBD brands offer quality products at a fair price. Do due diligence while looking for a CBD product and research on their makers. Find out everything you can about a company and the brand before you blindly fall for such “Free, Free, Free” lure. 

Pushing Hemp Seed Oil Instead of Hemp CBD 

Another reason for the confusion among users and abuse of the market is ignorance. Not only do you need to be wary about “fake CBD” and “free samples”, but you should also learn everything there is to know about how CBD is sourced and manufactured. 

If you have, you would know that hemp seed oil is not CBD oil derived from hemp. 

So, when you research on any brand, look for its ingredients on the label or their website. 

If it is Hempseed Oil, it will be listed as Cannabis Sativa Seed Oil.

If it is genuine CBD oil, you may see Cannabidiol, full-spectrum hemp, hemp oil, PCR (phytocannabinoid-rich) or PCR hemp extracts written on the label.

Also, look at their CoA for their products on their product webpages. 

Yes, they are lab tests, but not difficult for a layman to read and understand. It is meant for you, so it’s really quite simple. 

Hemp seed oil: Although a good carrier oil for CBD, it is not the same as CBD oil. So what is it? 

For that, you need to know where CBD oil is sourced. The best quality and most potent CBD oils are produced from hemp flowers. While the rest of the plant – like its leaves and shoots – may be used too. But, they have far less CBD content. 

The smaller seeds, in particular, have the least amount of it – traces at the best. Hemp seeds can be used to make hempseed milk or granola. They can also be cold-pressed to produce oil. But this oil is only good for cooking, making beauty products, or making paint. 

While hemp seed oil does have some benefits, like mild anti-inflammatory effects and skin moisturizer, it does not have sufficient levels of CBD to be called “CBD oil”. 

This means you would end up paying much for the product that it deserves. Intentionally or unintentionally, some companies try to push a cheaper product like hemp seed oil. 

Tricking Consumers with Products with low CBD content

Apart from hemp seed oil, there are other CBD products that don’t contain enough CBD to have any perceivable health benefits. 

Always look for the CBD content in mg on the label. This is the concentration of the CBD contained in the product. The total volume of the liquid does not guarantee CBD content. 

For instance, a 3 oz. bottle of tincture, priced at $50 and containing only 100 mg of CBD, may seem like a good deal. But, it is actually not. It is costing you $0.50/mg. A 1 oz. bottle, priced at $132 and containing 3000mg of CBD, is, in fact, a better deal ($0.04/mg). 

Making Sure You Get Quality Product 

By now, you must have understood that buying CBD oil isn’t as easy as you may have thought – click-click-click. 

You need to do a lot of research…

  • Research on how CBD oil is sourced, extracted, processed, purified, and the end product manufactured. 
  • Research on the companies and brands selling the products
  • Studying the CoAs, if they are provided by the companies. If they are not provided, they are obligated to provide one on request. 
  • Understanding the current market situation and the presence of synthetic cannabinoids, scammers, and cheap variants with tall claims.
  • The actual health benefits of CBD, so you don’t get lured by brands that make outrageous claims like curing cancer! 

Always make sure you get a high-quality CBD product when you place your order. Never let promotions, discounts or unrealistic claims fool you. 

When it comes to buying CBD, there is no bliss in ignorance, only suffering!


Debra BorchardtDebra BorchardtJune 19, 2019
CharlottesWeb.jpg

3min5270

Charlotte’s Web Holdings, Inc.  (TSX:CWEB)(OTCQX:CWBHF) reported its final hemp planting for its 2019 growing season. The company said that in order to meet growing demand the total acres planted for 2019 has been increased to 862, an 187% increase from 300 acres planted in 2018.

“Interest and demand for our products has been exceptional and growing rapidly. Our 2019 planting strategy ensures we will have the required raw materials to deliver on production targets for Charlotte’s Web products through 2020 and into 2021,” stated Deanie Elsner, CEO of Charlotte’s Web. “Our leading CBD hemp varieties under cultivation today are the foundation of our 2020 production plan.”

Charlotte’s Web said it uses an inventory model where it grows more hemp than it needs for the subsequent year to minimize the impact of farming risks and product shortfalls against forecasted rapid market growth. Dried hemp can be stored for years, with even more longevity in its extracted form. In 2016, 2017 and 2018, the company produced 41,000 lbs., 63,000 lbs. and 675,000 lbs., respectively, of dried hemp biomass.

A few weeks ago the company reported its earnings for the first quarter with revenue growing 66% to $21.7 million. The net income though dropped to $2.3 million from last year’s $3.1 million. The company delivered earnings per share that fell to $0.03 and diluted EPS of $0.02 versus last year’s $0.04. Operating expenses doubled from last year’s $6.4 million to this year’s $13.2 million.

Charlotte’s Web cultivates hemp outdoors in various regions across the United States to hedge against potential weather risks and other crop-related impacts. Of the 862 acres planted, 166 (19%) are in Colorado, 325 (38%) are in Kentucky, and 371 (43%) are in Oregon. The Colorado farms are operated by the company’s cultivation team while farms in Kentucky and Oregon employ family-owned contract farmers, supporting the important American agricultural economy through hemp farming.

All acres are cultivated using natural farming methods. An active supporter of organic farming, up to 457 acres, or 53% of the total acres planted for 2019 are designated for USDA organic certification, with additional organic expansion planned in subsequent years.

The company said it grows several hemp varieties, all of which contain high levels of CBD content but only trace THC amounts of less than 0.3%. Hemp varieties with high CBD potency reduce the amount of biomass required for CBD extracts, allowing for responsible farming practices by maximizing the production of cannabinoids, terpenes, and other beneficial botanical compounds.

 


Debra BorchardtDebra BorchardtJune 19, 2019
CannTrust3.png

3min3650

CannTrust Holdings Inc. (NYSE: CTST) shares popped over 5% in early trading on news that the company had formed a joint venture with California hemp grower Elk Grove Farming Company. CannTrust is a Canadian cannabis company founded by pharmacists and this would be the company’s entry into the United States. The company said it expects to invest roughly $20 million in the operation by the end of 2020. The shares were lately trading at $5.22.

CannTrust signed a non-binding Letter of Intent with Elk Grove that will provide access to over 3,000 acres of farmland for hemp production.  Elk Grove will be able to provide low-cost hemp with high cannabidiol (CBD) content. CannTrust and Elk Grove will each have 50% ownership of a new entity or joint venture.

The company said that prior to the commercial scale cultivation from the Joint Venture in 2020, CannTrust plans to execute on its processing strategy from the biomass produced from the Joint Venture, and its product development strategy. The company said that extracted product from the California operation in proprietary products has already been developed and that are ready for commercial production. The company specifically mentioned patented single-serve beverage pods.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity, which will leverage our expertise in standardized CBD-based product formulation, and will give the Company a foothold in the largest international CBD market in the world with an experienced and knowledgeable partner,” said Peter Aceto, Chief Executive Officer of CannTrust. “Following our successful equity offering, we have the liquidity we need to fund our ambitious growth plans including our greenhouse expansion in Niagara, our outdoor cultivation operation in British Columbia, our global footprint expansion and now our U.S. operation.”

According to the statement, Elk Grove has multi-generational experience in farming across a wide variety of commodities and value-added expertise in leading crop protection products, application, and input supply with operations throughout the State of California. “We are thrilled to be partnering with CannTrust. Our knowledge of farming operations in California coupled with CannTrust’s expertise in developing award-winning formulations is the perfect match to become a trusted supplier of CBD products in the U.S,” said Morgan Houchin of Elk Grove Farming Company.

 


Video StaffVideo StaffJune 4, 2019

1min5000

The Economics of the New Hemp Market is a panel that was held on May 7 at the Green Market Summit in Chicago. The legalization of hemp is so new that the regulations are still being written. Data will be key to unlocking this industry and industrial grade price assessments will be needed over the next few months to support futures trading on a major commodity exchange sometime early 2019. This panel was led by moderator Peter Vogel, CEO Leafwire and he was joined by Jonathan Rubin, Founder – Cannabis Benchmarks, Kevin Pilarski Chief Commercial Officer – Revolution and Bethany Gomez, Director of Research – Brightfield Group.


StaffStaffMay 14, 2019
hemp.jpg

4min3600

Hemptown Organics Corp. raised  C$24 million in a round of financing from Canaccord Genuity Corp.who served as the lead agent on the brokered portion of the financing on behalf of a syndicate of investors that included Sprott Capital, Beacon Securities, and Pacific International.

The investment will allow Hemptown to embark on a multi-state expansion, purchase $5.5M in Oregon CBD seeds, begin the build-out of its processing and extraction facilities, research team, as well as planting and harvesting of its 2019 crop of feminized hemp seeds.

“Successful companies in this sector will be those with the ability to build a scalable, vertically integrated multi-state company,” stated Rod Wolterman, Founder and Chairman, Hemptown USA. “We have assembled a well-respected team that has already produced some of the highest quality feminized hemp in the country here in Southern Oregon’s Emerald Triangle. The capital infusion will allow us to expand operations to Colorado, Kentucky, Northern California, ramp up processing capabilities and develop disruptive product formulations in the CPG sector. Needless to say, we’re very excited to be executing on our vision and delivering sustainably grown feminized hemp flower and biomass on a commercial scale.”

With this capital infusion, Hemptown USA is now poised to become a formidable multi-state operation within this rapidly growing industry. Hemptown reported that it had a first-year yield of 110,000 lbs of feminized hemp biomass. The company said it is one of the largest CBG producers in the U.S. with our purchase of 1 million rare CBG seeds for the 2019 growing season. It also said that it is producing some of the world’s most coveted strain profiles containing 15% – 20% full spectrum CBD, CBG and other cannabinoids and terpenes.

Currently, the company is growing 1500 acres in Oregon, Kentucky, and Colorado with the capability to more than double the acreage in 2020 and each year after.

Looking Ahead

Hemptown plans to continue farming more novel cannabinoid strains in large quantities. Such as CBC, CBDV, and CBGV. The company also plans on acquiring a cGMP nutraceutical facility to develop unique cannabinoid products for the health and wellness industry.

“Successful companies in this sector will be those with the ability to build a scalable, vertically integrated multi-state company,” stated Rod Wolterman, Founder and Chairman, Hemptown USA. “We have assembled a well-respected team that has already produced some of the highest quality feminized hemp in the country here in Southern Oregon’s Emerald Triangle. The capital infusion will allow us to expand operations to Colorado, Kentucky, Northern California, ramp up processing capabilities and develop disruptive product formulations in the CPG sector. Needless to say, we’re very excited to be executing on our vision and delivering sustainably grown  feminized hemp flower and biomass on a commercial scale.”

 

 


StaffStaffMay 9, 2019
img_hawaii.jpg

3min6160

Just two months after announcing the launch of Arcadia Specialty Genomics™, a new cannabis-dedicated division of agricultural crop improvement, the company has released images of its first crop of sun-grown, Hawaiian hemp. Arcadia’s new cannabis unit, cultivates six Hawaiian hemp strains on its 10-acre Hawaiian facility.

In March, the company revealed it had been granted an Industrial Hemp Pilot Program (“HIHPP”) License by Hawaii’s Department of Agriculture. The license allows for the cultivation of industrial hemp for the purposes of agricultural and academic research. Hemp and hemp products produced under the program may be commercially sold.

With a 10-acre field station in Hawaii, Arcadia is producing its first research crop of hemp to test the impact of climate and geography on crop parameters like yield and quality. Arcadia Specialty Genomics’ scientists and agronomists are evaluating and characterizing the performance of a number of local strains against various climate and biological conditions to understand the attributes of each, as well as identify opportunities for improvement. In addition, the company has hired full time staff at its Hawaii facility to oversee the ongoing research and grow operations.

“It’s highly gratifying to see our first hemp research crop taking root in Hawaii, having planted six different Hawaiian strains,” said Matt Plavan, president of Arcadia Specialty Genomics and CFO of Arcadia Biosciences. “In order to solve for crop variability – a major concern for U.S. hemp farmers – we first need to understand its drivers. We’re applying the sound, scientific approaches we’ve used to improve other crops, such as wheat, to create new breeds of superior hemp.”

Hawaii is the first state where Arcadia Specialty Genomics has commenced its research and cultivation of hemp in federal and state legal cannabis markets, using non-GMO techniques to produce superior U.S. hemp crops.

While traditional agricultural crops can be difficult to grow and export economically in Hawaii, the rich soil and warm climate are ideal for cultivating high-value crops such as hemp.

Arcadia Biosciences is a recognized leader bringing deep experience and established capabilities in this kind of crop innovation and optimization, delivering proven results safflower, wheat and durum such as:

A 100 percent increase in the production of omega-6 GLA for safflower
Two to six times more fiber than standard wheat and durum with its proprietary GoodWheat™ flour
A 65 percent reduction in allergenic gluten content in its GoodWheat™ flour
30 percent more lysine, an essential amino acid, in GoodWheat™ compared to standard wheat
The company expects to harvest its first crop of Hawaiian-grown research hemp this summer.

 

 


AxisWireAxisWireMay 7, 2019
img_hawaii2.jpg

8min5470

Arcadia Biosciences’ Hawaiian Hemp Farm in Full Bloom

Arcadia Specialty Genomics, the company’s new cannabis unit, cultivates six Hawaiian hemp strains on its 10-acre Hawaiian facility.

DAVIS, Calif. (May 7, 2019) /AxisWire/ – Just two months after announcing the launch of Arcadia Specialty Genomics™, a new cannabis-dedicated division of agricultural crop improvement leader Arcadia Biosciences, the company is releasing images of its first crop of sun-grown, Hawaiian hemp.

Arcadia Specialty Genomics focuses on the development of novel cannabis varieties possessing productivity, pest resistance and crop quality traits for license to cultivators in federal and state legal markets, and as products such as hemp-derived CBD oils for the nutraceutical and food industries.

In March, the company revealed it had been granted an Industrial Hemp Pilot Program (“HIHPP”) License by Hawaii’s Department of Agriculture. The license allows for the cultivation of industrial hemp for the purposes of agricultural and academic research. Hemp and hemp products produced under the program may be commercially sold.

With a 10-acre field station in Hawaii, Arcadia is producing its first research crop of hemp to test the impact of climate and geography on crop parameters like yield and quality. Arcadia Specialty Genomics’ scientists and agronomists are evaluating and characterizing the performance of a number of local strains against various climate and biological conditions to understand the attributes of each, as well as identify opportunities for improvement. In addition, the company has hired full time staff at its Hawaii facility to oversee the ongoing research and grow operations.

“It’s highly gratifying to see our first hemp research crop taking root in Hawaii, having planted six different Hawaiian strains,” said Matt Plavan, president of Arcadia Specialty Genomics and CFO of Arcadia Biosciences. “In order to solve for crop variability – a major concern for U.S. hemp farmers – we first need to understand its drivers. We’re applying the sound, scientific approaches we’ve used to improve other crops, such as wheat, to create new breeds of superior hemp.”

Hawaii is the first state where Arcadia Specialty Genomics has commenced its research and cultivation of hemp in federal and state legal cannabis markets, using non-GMO techniques to produce superior U.S. hemp crops.

While traditional agricultural crops can be difficult to grow and export economically in Hawaii, the rich soil and warm climate are ideal for cultivating high-value crops such as hemp.

Arcadia Biosciences is a recognized leader bringing deep experience and established capabilities in this kind of crop innovation and optimization, delivering proven results safflower, wheat and durum such as:

  • A 100 percent increase in the production of omega-6 GLA for safflower
  • Two to six times more fiber than standard wheat and durum with its proprietary GoodWheat™ flour
  • A 65 percent reduction in allergenic gluten content in its GoodWheat™ flour
  • 30 percent more lysine, an essential amino acid, in GoodWheat™ compared to standard wheat

The company expects to harvest its first crop of Hawaiian-grown research hemp this summer. For more information, visit www.arcadiabio.com.

About Arcadia Specialty Genomics

Arcadia Specialty Genomics is a strategic business unit of Arcadia Biosciences, Inc. leveraging the market-leading capabilities of its parent company to deliver crop innovation into developing proprietary, industry-leading cannabis germplasm. Focused on productivity, pest resistance and favored quality traits, Arcadia Specialty Genomics’ innovations serve the state- and federally-legal nutraceutical, food and industrial markets. For more information, visit www.arcadiaspecialtygenomics.com

About Arcadia Biosciences, Inc.

Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the environmental impact of agriculture. For more information, visit www.arcadiabio.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia Specialty Genomics’ expectations about the cannabis industry and potential demand for our products; the uncertainty of the laws and regulations relating to cannabis and products derived therefrom; the inherent uncertainty associated with the development of new projects; our ability to obtain proper licenses and successfully complete research programs related to cannabis; the acceptance of our products in the marketplace; the impact of competitive products and pricing;  risks related to costs, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process; our partners’ and affiliates’ ability to develop commercial products incorporating cannabis related traits, and complete the regulatory review process for such products; our compliance with laws and regulations that impact our business, and changes to such laws and regulations; our future capital requirements and ability to satisfy our capital needs; our ability to develop, enforce and defend our intellectual property rights; and the other risks set forth in our filings with the Securities and Exchange Commission from time to time, including the risks set forth in our Annual Report on Form 10-K for the year ended December 31, 2018 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

Twitter: @ArcadiaAg on Twitter
LinkedIn: Arcadia Biosciences

Press Contacts:

Trailblaze PR
Lisa Weser
lisa@trailblazepr.com


StaffStaffApril 30, 2019
Texas.jpg

4min4640

The Texas Tribune reported on Monday that the House of Representatives approved a bill that would decriminalize possession of cannabis. Rep. Joseph Moody (D), the chief sponsor of the bill, still had to amend it in order to get the bill approved. His original version had a lower fine of $250 and it would have dropped down low-level possession to a civil infraction instead of a class C misdemeanor.

Still, the paper reported that the chances of the bill turning into law would be slim. “After the House grants final approval for the bill — usually just a formality — it will head to the Senate, where presiding officer Lt. Gov. Dan Patrick has expressed opposition to the idea of loosening marijuana possession penalties.” The resistance is attributed to the fear that each move to loosen cannabis laws is another step towards full legalization.

If Texas manages to pass the law, it would become the 25th state to decriminalize cannabis. “Texans have suffered under failing marijuana policies for far too long,” Heather Fazio, director of Texans for Responsible Marijuana Policy, said. “Rep. Moody’s bill will help preserve valuable public safety resources and keep a marijuana charge from derailing someone’s life. Like a majority of Texas voters, Democratic and Republican lawmakers agree that marijuana laws need to change.”

Medical marijuana is legal in the state but on a very restrictive level. There is only one approved condition, which is intractable epilepsy. Several pieces of legislation have been filed in order to expand the condition list.

Hemp Farming Legalized

Just last week, The Texas House approved a bill that would allow farmers in the state to legally grow industrial hemp. House Bill 1325 from state Rep. Tracy King, D-Batesville, would also legalize hemp and hemp-derived extracts like CBD oil as long as they contain no more than 0.3% THC. “HB 1325 is right-to-farm legislation that will allow Texas farmers the opportunity to cultivate a drought-resistant cash crop — that being hemp,” King told other House members.

The bill has now headed to the Senate for approval. Texas Agriculture Commissioner Sid Miller is a strong supporter of industrial hemp production as a new market opportunity for Texas farmers to expand their operations and grow alternative crops.  Once authorized by the Legislature, TDA said it will create rules regarding licensing, production, testing, seed certification and other oversight as necessary.

“There’s no good reason for Texas farmers and ranchers not to have hemp as a crop option,” said Gene Hall, a spokesman for the Texas Farm Bureau. “I suspect a lot of farmers will choose this option once it’s available. It’s a drought-tolerant crop and can be grown anywhere where cropping is prevalent right now.”

 


Debra BorchardtDebra BorchardtApril 29, 2019
shutterstock_511330249-1-1280x1778.jpg

4min6910

Canopy Growth Corporation  (TSX: WEED) (NYSE: CGC) announced a key milestone in establishing its Hemp Industrial Park in the Southern Tier region of New York State. It has secured a 308,000 sq. ft. facility on a 48-acre property in Kirkwood, NY.

The company said that design development would begin immediately with construction expected to start this summer. Canopy said in a statement that its vision for the property is to build the infrastructure necessary to support hemp-derived cannabinoid extraction and related manufacturing together with providing an opportunity for participation by other businesses in the hemp industry.

“As we establish a stronger foothold in the exciting US market, we want to do so in a way that prioritizes local vendors and creates meaningful career opportunities for people in the communities where we operate,” said Bruce Linton, Chairman & co-CEO, Canopy Growth. “The vision for our investment is to create an eco-system that inspires new entrepreneurs and generates more economic stimulus than a single company can offer. As we build the facilities, we’ll also attract like-minded businesses who share our excitement for the emerging hemp and hemp-derived cannabinoid markets.”

New York State of Mind

In a boost to the New York cannabis industry Canopy said it will begin hiring senior leadership in late 2019 and recruit the full workforce in mid-2020. Canopy Growth also noted that it has also begun securing farm capacity to supply enough hemp for its own future extraction and formulation activities within the park. The company intends to prioritize farms within New York State for the supply of hemp at this site.

“We welcome Canopy Growth to Broome County with open arms. We haven’t seen an investment like this in Broome in some time, and we’re so excited a company like them is setting up shop in our area,” said Broome County Executive Jason Garnar. “With Canopy Growth coming to Broome County we look forward to seeing the benefits in job investment.”

Now that Canopy Growth has secured its building, the company said it expects to begin work quickly on Pine Camp Drive and with local construction teams retrofitting the facility, operations will scale-up quickly. It was once a vacuum parts building. It is expected that the operations will create hundreds of new local full-time positions, in addition to the contracted construction workers.

NY Hemp

New York State granted a hemp license to Canopy Growth in January of this year, allowing Canopy to establish operations in the state and build a facility for hemp-derived cannabinoid extraction and processing for various applications. The new hemp facility will be capable of producing tons of hemp extract on an annual basis. In 2018, Canopy Growth acquired leading hemp research company, ebbu, Inc. The R&D, along with ebbu’s Intellectual Property will be applied directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities.

Canopy also said in its statement that it will begin approaching third-party organizations to join the ecosystem. Canopy Growth is eager to attract businesses and researchers focused on every application of the hemp crop such as fibers, seeds, and hemp-derived cannabinoids.


Caroline CahillCaroline CahillApril 5, 2019
shutterstock_1093553171.jpg

5min12760

The CBD industry has been moving full steam ahead in 2019, bolstered by the 2018 Farm Bill and advancements on the federal level to ensure cannabis banking services, but that progress hasn’t been enough for some financial services institutions to continue working with the industry.

On March 14, 2019, Elavon, a payment processing subsidiary of U.S. Bank, notified its hemp and CBD clients that it had recategorized hemp and cannabidiol-based merchants as a prohibited business type and that accounts for such merchants would be closed within 45 days.  

“After several months supporting this merchant segment, it has become clear that the pace of an evolving Federal and State regulatory framework makes it extremely difficult to validate the qualifications required to operate within this industry,” said Elavon in an email to its hemp and CBD clients.

As an Elavon partner, FINCANN, a cannabis banking financial network, received Elavon’s notice and began sourcing solutions for its clients at once.

“We immediately reviewed remaining available options and within 24 hours had viable USA-based excellent alternatives available,” said Nathaniel Gurien, founder and CEO of FINCANN. “Since Elavon is not terminating their existing portfolio of CBD merchants until May 15, some merchants opted to immediately apply to one of our alternatives, others decided to wait and see until at least mid-April.”

Elavon isn’t the only merchant services provider rethinking its hemp and CBD clients. On March 19, Cannovia, a maker of CBD-infused products, was notified by Stripe that its account would be terminated. Having just launched its online storefront on March 14, Cannovia attempted to appeal Stripe’s decision but was denied.

“Prior to the notification of the merchant services cancellation, we were not fully aware of the limitations of the banking industry to support the needs of the CBD industry,” said Brian Baum, the CEO of Cannovia.

With both Stripe and Elavon out of the picture, Cannovia soon learned that finding a merchant services provider on its own wouldn’t be easy.

According to Baum, “What became clear was that the options were limited and any banks willing to consider supporting the industry were beginning to utilize the services of intermediaries such as FINCANN to assist them in managing the sheer volume of entities looking for merchant services solutions.”

Linking up with FINCANN to secure a new merchant services provider allowed Cannovia to remain operational and avoid any major interruptions.

Meanwhile, both financial institutions and industry stakeholders continue to keep an eye on the SAFE Banking Act, which would provide certain protections for depository institutions that work with cannabis-related businesses as well as the businesses themselves. The House Committee on Financial Services is currently drafting a report on the act to present to the House of Representatives. If the full House approves the bill, the Senate will vote on it.   

“If the SAFE Banking Act overcomes its estimated 40% likelihood of passing the Senate, it will only encourage banks currently contemplating ‘dipping their feet into the water’ to ‘take the plunge,’” Gurien said. Once financial institutions take the plunge, legal cannabis-related businesses will be able to bank just like any other legal business.

 



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 hours

My week on Twitter 🎉: 4 Mentions, 6.44K Mention Reach, 8 Likes, 2 Retweets, 8.87K Retweet Reach. See yours with…

@GreenMarketRpt – 15 hours

‘Too costly, not enough evidence it works’, says in blow to campaigners

@GreenMarketRpt – 1 day

It’s time for your : August 21, 2019

Back to Top

You have Successfully Subscribed!